Levodropropizina como Antitusivo
Eficacia Clínica
- La levodropropizina es un antitusivo periférico altamente efectivo para la bronquitis crónica y aguda, con aproximadamente 75% de supresión de la tos y un perfil de seguridad superior a los opioides, según el American College of Chest Physicians 1, 2, 3
- Reduce la tos en aproximadamente 75% en pacientes con bronquitis crónica o aguda, según el American College of Chest Physicians 1, 2, 3, 4, 5, 6
- Las guías del American College of Chest Physicians recomiendan la levodropropizina para el alivio sintomático a corto plazo de la tos en bronquitis crónica o aguda, con un nivel de evidencia bueno y un grado de recomendación A 7
Comparación con Otros Antitusivos
- La levodropropizina es tan efectiva como la dihidrocodeína para suprimir la tos en cáncer de pulmón, con somnolencia significativamente menor, según el American College of Chest Physicians 1, 2, 3, 4, 5, 6, 8
- Tiene un perfil de seguridad superior a los opioides, sin sedación significativa, sin depresión respiratoria, y sin efectos sobre el centro respiratorio, según el American College of Chest Physicians 8
Consideraciones Prácticas
- La dosificación típica es de 75 mg tres veces al día en adultos, según el American College of Chest Physicians 8
- La levodropropizina es generalmente muy bien tolerada, con efectos adversos leves en solo 3% de pacientes, y sin efectos sedantes significativos, según el American College of Chest Physicians 2, 4, 8
- No está aprobada para uso en Estados Unidos, pero está disponible en otros países, según el American College of Chest Physicians 1, 2, 3, 4, 5, 6
Safety of Levodropropizine vs Butamirate Citrate in Diabetic Patients
Evidence-Based Safety Profile Comparison
- The American College of Chest Physicians provides evidence recommending levodropropizine for symptomatic relief of cough in bronchitis, with typical dosing of 75 mg three times daily, although the provided reference is not valid, an alternative reference shows levodropropizine was equally effective as dihydrocodeine for cough suppression but caused significantly less somnolence (8% vs 22%) 9
- Butamirate citrate has limited high-quality evidence, with only one double-blind randomized trial showing benefit specifically in lung cancer patients (n=14 subgroup), demonstrating improvement in 7 of 7 patients versus 2 of 7 with control, and the 2017 guidelines classify butamirate evidence as Grade 2C (low quality) 10, 11
Practical Prescribing Algorithm
- Reserve butamirate citrate for cases where levodropropizine is unavailable or not tolerated, recognizing its weaker evidence base 10, 11
Important Caveats
- Many over-the-counter cough syrups contain subtherapeutic levels of active ingredients; ensure adequate dosing when prescribing 10
- Glycerol-based cough syrups may be less effective for profound cough in diabetic patients with multiple comorbidities 10
Levodropropizine for Dry Cough: Efficacy, Safety, Dosing, and Availability
Efficacy in Non‑Productive Cough
- In healthy adults with dry (non‑productive) cough, levodropropizine achieves approximately 75 % cough suppression, offering superior tolerability compared with opioid antitussives. 12
Safety Profile Compared with Opioid Antitussives
- In head‑to‑head trials, the somnolence rate with levodropropizine is about 8 %, markedly lower than the 22 % observed with dihydrocodeine. 12
- Levodropropizine is not associated with opioid‑related complications such as constipation, dependence, or respiratory depression/suppression. 12
Practical Dosing and Treatment Duration
- For a healthy adult presenting with isolated dry cough, the recommended regimen is levodropropizine 75 mg three times daily, administered for 7 days—the duration evaluated in clinical studies. 12
Availability and Regulatory Status
- Levodropropizine is not approved in the United States but is widely available in Europe and other regions. 12
Levodropropizina for Acute Non‑Productive Cough in Adults – Evidence‑Based Guidance
Efficacy
- Levodropropizina provides a risk‑benefit profile that is superior to other antitussives; its cough‑suppressing efficacy is comparable to opioid‑based agents but it does not cause respiratory depression, constipation, dependence, or marked sedation【13】.
- In a double‑blind randomized trial of 140 adults, levodropropizina 75 mg three times daily achieved equivalent reduction in cough severity and nocturnal awakenings compared with dihydrocodeine 10 mg three times daily【13】【14】.
Safety
- Somnolence was reported in 8 % of patients receiving levodropropizina versus 22 % with dihydrocodeine, highlighting a markedly better tolerability profile【13】.
- Dihydrocodeine was associated with respiratory depression, constipation, and dependence, adverse effects that were absent with levodropropizina【13】.
Recommended Dosage
- Levodropropizina: 75 mg orally three times daily for a 7‑day course in adults with acute non‑productive cough【15】.
- Dextromethorphan (alternative): 10–15 mg orally three to four times daily, not to exceed 120 mg per day【14】【15】.
CHEST Guideline Recommendations (2017)
| Step | Recommendation | Evidence Grade |
|---|---|---|
| 1 | Begin with simple demulcent syrups (e.g., glycerol‑based) | 2C【14】 |
| 2 | If demulcents fail, add opioid‑derived antitussives | 2C【14】 |
| 3 | For cough refractory to opioids, use peripheral antitussives such as levodropropizina, moguisteine, levocloperastine, or cromoglicate | 2C【14】 |
| 4 | If peripheral agents fail, consider local anesthetic antitussives (consensus) | Consensus【14】 |
- The CHEST guidelines specifically endorse levodropropizina for cough that is resistant to opioid therapy, when the drug is available【14】【15】.
Treatment Duration & Re‑evaluation
- Antitussive therapy should be discontinued after 3–7 days if no clinical improvement is observed, and the underlying diagnosis should be reassessed【14】【15】.
Risk Assessment Prior to Local Anesthetic Use
- Before employing local anesthetic antitussives in frail patients, clinicians should evaluate the risk of aspiration【14】【15】.